ALNY
Alnylam Pharmaceuticals Inc. Healthcare - Biotechnology Investor Relations →
Alnylam Pharmaceuticals Inc. (ALNY) closed at $278.09 as of 2026-06-19, trading 8.8% above its 200-week moving average of $255.54. The stock is currently moving closer to the line, down from 10.8% last week. With a 14-week RSI of 30, ALNY is in oversold territory.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.80 ratio) is neutral — neither side is clearly dominating.
Over the past 1102 weeks of data, ALNY has crossed below its 200-week moving average 15 times. On average, these episodes lasted 20 weeks. Historically, investors who bought ALNY at the start of these episodes saw an average one-year return of +23.0%.
With a market cap of $37.1 billion, ALNY is a large-cap stock. The company generates a free cash flow yield of 0.6%. Return on equity stands at 90.4%, indicating strong profitability. The stock trades at 34.5x book value.
Share count has increased 6.8% over three years, indicating dilution.
Over the past 21.2 years, a hypothetical investment of $100 in ALNY would have grown to $3841, compared to $923 for the S&P 500. That represents an annualized return of 18.8% vs 11.1% for the index — confirming ALNY as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ALNY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ALNY Crosses Below the Line?
Across 15 historical episodes, buying ALNY when it crossed below its 200-week moving average produced an average return of +17.7% after 12 months (median +3.0%), compared to +19.4% for the S&P 500 over the same periods. 53% of those episodes were profitable after one year. After 24 months, the average return was +42.4% vs +40.8% for the index.
Each line shows $100 invested at the moment ALNY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices ALNY would reach each dislocation threshold.
Dislocation Price Levels
Prices where ALNY's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $267.49 | Unusually cheap — potential buy zone |
| Value | +1σ | $279.21 | Cheap vs. own history |
| Fair Value | +0σ | $292.00 | Historical mean behavior |
| Expensive | -1σ | $306.02 | Expensive vs. own history |
| Deep Expensive | -2σ | $321.45 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from ALNY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
ALNY has crossed below its 200-week MA 15 times with an average 1-year return of +23.0% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 2008 | Dec 2008 | 2 | 5.6% | -6.3% | +1447.5% |
| Feb 2009 | Jun 2009 | 15 | 21.3% | -10.4% | +1333.5% |
| Jul 2009 | Jul 2009 | 2 | 7.0% | -18.6% | +1318.1% |
| Sep 2009 | Jul 2012 | 146 | 66.6% | -43.7% | +1189.2% |
| Feb 2016 | Mar 2016 | 7 | 8.2% | -23.5% | +367.0% |
| May 2016 | May 2016 | 3 | 20.4% | -0.9% | +400.6% |
| Jun 2016 | Aug 2016 | 8 | 19.3% | +15.3% | +340.2% |
| Aug 2016 | Sep 2016 | 2 | 0.9% | +28.5% | +302.0% |
| Sep 2016 | Jun 2017 | 37 | 52.7% | +73.3% | +310.3% |
| Sep 2017 | Sep 2017 | 2 | 3.2% | +47.9% | +277.4% |
| Sep 2018 | Mar 2019 | 26 | 27.2% | -7.3% | +217.7% |
| Apr 2019 | Sep 2019 | 21 | 18.8% | +68.7% | +238.8% |
| Sep 2019 | Oct 2019 | 2 | 4.6% | +76.2% | +261.1% |
| Oct 2023 | Nov 2023 | 6 | 9.0% | +82.9% | +71.9% |
| Feb 2024 | Jun 2024 | 20 | 16.7% | +62.4% | +63.6% |
| Average | 20 | — | +23.0% | — |
Frequently Asked Questions
Is ALNY below its 200-week moving average?
No. Alnylam Pharmaceuticals Inc. (ALNY) is currently 8.8% above its 200-week moving average of $255.54. It would need to fall to $255.54 to cross below the line.
What is ALNY's 200-week moving average price?
Alnylam Pharmaceuticals Inc.'s 200-week moving average is $255.54 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ALNY drops below its 200-week moving average?
ALNY has crossed below its 200-week moving average 15 times in our data. On average, buying at that moment produced a one-year return of +23.0%. These dips have historically been decent entry points. These episodes lasted 20 weeks on average.
Is ALNY a good value right now?
Here's what our data says about ALNY as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 30 (oversold). Free cash flow yield is 0.6%. Return on equity is 90.4%. Price-to-book is 34.5x. This is not a buy or sell recommendation — always do your own research.
How does ALNY compare to the S&P 500?
Over the past 21.2 years, $100 invested in ALNY would have grown to $3841, compared to $923 for the S&P 500. That's 18.8% annualized vs 11.1% for the index. ALNY has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19